• Merck & Co.’s third-quarter 2026 GAAP earnings per share fell 12% year over year to $2.04.
• Sales rose 5% year over year to $18.09 billion, while WINREVAIR sales jumped 93% to $694 million.
• The FDA accepted sac-TMT for priority review in previously treated endometrial cancer, setting a June 15, 2027, decision deadline.
• Full-year 2026 sales guidance narrowed to $66.8 billion–$67.3 billion, raising the lower end from $66.3 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290630BIZWIRE_USPR_____20261029_BW138599) on October 29, 2026, and is solely responsible for the information contained therein.